Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1–G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases

• Published in: Annals of surgical oncology Vol. 23; no. Suppl 5; pp. 981 - 989
• Main Authors: Bertani, Emilio, Fazio, Nicola, Radice, Davide, Zardini, Claudio, Grana, Chiara, Bodei, Lisa, Funicelli, Luigi, Ferrari, Carlo, Spada, Francesca, Partelli, Stefano, Falconi, Massimo
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2016; Springer Nature B.V
• Subjects: Adult; Disease-Free Survival; Dose Fractionation, Radiation; Female; Humans; Ki-67 Antigen - metabolism; Liver Neoplasms - metabolism; Liver Neoplasms - radiotherapy; Liver Neoplasms - secondary; Male; Medicine; Medicine & Public Health; Middle Aged; Neuroendocrine Tumors - metabolism; Neuroendocrine Tumors - secondary; Neuroendocrine Tumors - therapy; Octreotide - analogs & derivatives; Octreotide - therapeutic use; Oncology; Organometallic Compounds - therapeutic use; Pancreatectomy; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; Pancreatic Tumors; Prospective Studies; Radiopharmaceuticals - therapeutic use; Radiotherapy, Adjuvant; Receptors, Peptide - therapeutic use; Surgery; Surgical Oncology; Survival Rate; Tumor Burden; Liver Metastasis; Propensity Score; National Comprehensive Cancer Network; Neuroendocrine Tumor; Overall Survival

Background A low burden of disease represents an independent favorable prognostic factor of response to peptide receptor radionuclide therapy (PRRT) in patients affected by gastro-entero-pancreatic neuroendocrine tumors. However, it is not clear whether this is due to a lower diffusion of the diseas...